A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors.
Ursolic acid liposome (UAL), a new antitumor drug, has potential therapeutic value. However, limited clinical data exists regarding multiple-dose safety, antitumor activity, and the recommended dose (RD) of UAL for subjects with advanced solid tumors. All subjects were intravenously administered UAL...
| Published in: | BioMed Research International Vol. 2015; pp. 1 - 8 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | clinical trial research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
3/19/2015
|
| Online Access: | View this record in EBSCOhost |